Publication
Nanomedicine-Empowered CAR-T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy.
Can Huang, Xuyan Zhang, Yuanyin Teng, Zhongsong Zhang, Bing Wang, Panpan Gu, Xiang Deng, Dianwen Wang, Hongli Xiao, Lingli Zou, Meng Zhao, Caifeng Zheng, Gaochun Zeng, Jianyun Li, Zoufang Huang
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Multiple myeloma (MM) remains a difficult-to-cure hematologic malignancy. Although B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy has substantially deepened clinical responses in patients with relapsed/refractory MM, its broader clinical application…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMultiple Myelomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available